Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer

doi:10.3748/wjg.v31.i21.106939

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (279)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-6) series.

Item

Count

PDF

HTML

148

Figures (1-7)

Tables (1-6)

Sum=248

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=18

Jun 7, 2025 (publication date) through Jun 9, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Jun 7, 2025; 31(21): 106939
Published online Jun 7, 2025. doi: 10.3748/wjg.v31.i21.106939

Table 2 Comparison of short-term efficacy between two groups of microsatellite stable metastatic colorectal cancer

Group	Number	PR	SD	PD	DCR (%)
Control group	77	7	34	36	57.14
Experimental group	26	3	17	6	76.92
χ² value	-	-	2.706	3.585	3.5847
P value	-	0.71¹	0.1	0.058	0.058

¹Fisher’s exact test.

The control group received chemotherapy combined with bevacizumab; the experimental group received chemotherapy combined with bevacizumab and anti- programmed death 1 immunotherapy. PR: Partial response; SD: Stable disease; PD: Progressive disease; DCR: Disease control rate.

Citation: Gao Z, Wang XY, Shen ZG, Liu JH, Wang XY, Wu SK, Jin X. Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer. World J Gastroenterol 2025; 31(21): 106939
URL: https://www.wjgnet.com/1007-9327/full/v31/i21/106939.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i21.106939